ArticleMedical science monitor : international medical journal of experimental and clinical research2026
Effect of Low-Dose Vonoprazan on Hepatic Cytochrome P450 Activity By 13C-Aminopyrine Breath Test in Healthy Subjects.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Proton pump inhibitors (PPIs) affect hepatic drug metabolism via cytochrome P450 (CYP) enzymes, but the impact of potassium-competitive acid blockers (P-CABs), such as vonoprazan (VPZ), is not fully understood. This study aimed to evaluate whether maintenance-dose VPZ influences hepatic CYP activity using the 13C-aminopyrine breath test (13C-ABT). MATERIAL AND METHODS Twenty healthy subjects aged 18 years or older were recruited. Each participant underwent 13C-ABT under 2 conditions: without treatment (control) and after 8 days of 10 mg VPZ once daily. After oral administration of 100 mg 13C-aminopyrine, breath samples were collected before dosing and every 15-30 minutes for 3 hours. The delta-over-baseline (DOB) ratio, reflecting ¹³CO₂/¹²CO₂, was measured using infrared spectroscopy. RESULTS Nineteen participants (median age 24 years; 10 men, 9 women) completed the study. In the control condition, DOB values increased from 15 minutes after dosing and reached a peak at 49.7±35.8 minutes. The VPZ condition showed no significant differences in the DOB curve compared to the control condition (P=0.316). The area under the DOB curve over 3 hours was comparable between conditions, with a geometric mean ratio of 1.09 (90% confidence interval 0.97-1.23). Peak values and time to peak were also similar between 2 conditions. CONCLUSIONS Administration of 10 mg of VPZ did not significantly affect hepatic CYP activity as assessed by the 13C-ABT, suggesting that VPZ at a maintenance dose has minimal effect on hepatic drug metabolism and drug-drug interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.